Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Publication date: August 2019Source: European Urology, Volume 76, Issue 2Author(s): Laurence Albiges, Tom Powles, Michael Staehler, Karim Bensalah, Rachel H. Giles, Milan Hora, Markus A. Kuczyk, Thomas B. Lam, Börje Ljungberg, Lorenzo Marconi, Axel S. Merseburger, Alessandro Volpe, Yasmin Abu-Ghanem, Saeed Dabestani, Sergio Fernández-Pello, Fabian Hofmann, Teele Kuusk, Rana Tahbaz, Axel BexAbstractRecent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies.Patient summaryPembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.
Source: European Urology - Category: Urology & Nephrology Source Type: research